{"id":4440,"date":"2025-12-04T13:26:22","date_gmt":"2025-12-04T10:26:22","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4440"},"modified":"2025-12-05T20:45:28","modified_gmt":"2025-12-05T17:45:28","slug":"nadir-hastaliklarin-tanisinda-yapay-zeka-donemi-copy","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4440","title":{"rendered":"Nadir Hastal\u0131klar\u0131n Tan\u0131s\u0131nda Yapay Zek\u00e2 D\u00f6nemi"},"content":{"rendered":"\n

MLP Care, Alexion AstraZeneca Nadir Hastal\u0131klar ve Evideep, nadir hastal\u0131klar konusunda yapay zeka kullan\u0131m\u0131n\u0131 hedefleyen ortak bir dijital d\u00f6n\u00fc\u015f\u00fcm projesine imza att\u0131. \u00dc\u00e7 kurumun i\u015f birli\u011fiyle hayata ge\u00e7irilecek PNH Tan\u0131s\u0131 i\u00e7in Dijital D\u00f6n\u00fc\u015f\u00fcm Projesi, T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n erken tan\u0131s\u0131ndaki \u00f6nc\u00fc dijital giri\u015fimlerden biri olacak.<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sa\u011fl\u0131k sekt\u00f6r\u00fcnde yapay zeka kullan\u0131m\u0131 ve dijital d\u00f6n\u00fc\u015f\u00fcm konusunda T\u00fcrkiye\u2019nin en \u00f6nemli anla\u015fmalar\u0131ndan biri imzaland\u0131. MLP Care, Alexion AstraZeneca Nadir Hastal\u0131klar ve Evideep\u2019in ortak imzas\u0131yla T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n tan\u0131 s\u00fcre\u00e7lerinde yeni bir d\u00f6nem ba\u015fl\u0131yor. PNH (Nadir Hastal\u0131klar) Tan\u0131s\u0131 i\u00e7in Dijital D\u00f6n\u00fc\u015f\u00fcm Projesi, T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n dijital y\u00f6netimi alan\u0131ndaki \u00f6nc\u00fc bir giri\u015fim olarak dikkat \u00e7ekiyor.<\/p>\n\n\n\n

Yerli teknoloji ile sa\u011fl\u0131k sistemine katk\u0131<\/strong><\/p>\n\n\n\n

Projenin imza t\u00f6reni, MLP Care, Alexion AstraZeneca Nadir Hastal\u0131klar ve Evideep\u2019in y\u00f6neticilerinin kat\u0131l\u0131m\u0131yla ger\u00e7ekle\u015fti. T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n y\u00f6netimi, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n 2023-2027 Nadir Hastal\u0131klar Sa\u011fl\u0131k Strateji Belgesi ve Eylem Plan\u0131 \u00e7er\u00e7evesinde h\u0131zla geli\u015fiyor. \u00dc\u00e7 kurumun imzalad\u0131\u011f\u0131 PNH Tan\u0131s\u0131 i\u00e7in Dijital D\u00f6n\u00fc\u015f\u00fcm Projesi, bu alanda yap\u0131lan ilk i\u015f birli\u011fi oldu. Proje ile alanlar\u0131nda 3 \u00f6nc\u00fc kurum; sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131n\u0131n do\u011fru ve h\u0131zl\u0131 y\u00f6nlendirme yetkinli\u011finin art\u0131r\u0131lmas\u0131, dijital tan\u0131 programlar\u0131n\u0131n yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131, yerli teknoloji ile sa\u011fl\u0131k sistemine katk\u0131 sunulmas\u0131 ve \u00fclkemizde nadir hastal\u0131klar\u0131n veriye dayal\u0131 y\u00f6netimi gibi alanlarda somut katk\u0131 sa\u011flayacak.<\/p>\n\n\n\n

Nadir hastal\u0131klarda 5 y\u0131l\u0131 bulan tan\u0131 s\u00fcresi k\u0131salacak<\/strong><\/p>\n\n\n\n

Ara\u015ft\u0131rmalara g\u00f6re, Paroksismal Nokt\u00fcrnal Hemoglobin\u00fcri (PNH) gibi nadir hastal\u0131\u011f\u0131 olan bir hastan\u0131n kesin tan\u0131 almas\u0131 ortalama 5 y\u0131l\u0131 bulabiliyor. Bu zaman zarf\u0131nda hastalar 8 farkl\u0131 uzmana ba\u015fvuruyor ve vakalar\u0131n yakla\u015f\u0131k y\u00fczde 35-40\u2019\u0131nda yanl\u0131\u015f tan\u0131 sonucu hastalar\u0131n do\u011fru tedaviye eri\u015fimi gecikiyor.<\/p>\n\n\n\n

\u00dc\u00e7 kurumun liderli\u011finde y\u00fcr\u00fct\u00fclen projenin hayata ge\u00e7mesiyle, yapay zek\u00e2 temelli algoritmalar kullan\u0131larak PNH hastal\u0131\u011f\u0131nda oldu\u011fu gibi risk ta\u015f\u0131yan nadir hastal\u0131klara sahip olan ki\u015filer sa\u011fl\u0131k profesyonelleri taraf\u0131ndan daha erken fark edilecek ve zaman\u0131nda, do\u011fru merkezlere ve uzmanlara y\u00f6nlendirilebilecek. Projede MLP Care\u2019in g\u00fc\u00e7l\u00fc ve yayg\u0131n hastane a\u011f\u0131 ile tecr\u00fcbeli uzman hekim kadrosu, Alexion AstraZeneca Nadir Hastal\u0131klar grubunun 30 y\u0131ll\u0131k global nadir hastal\u0131k deneyimi ve Evideep\u2019in teknolojik yetkinlikleri bir araya geldi. Bu kapsamda, b\u00fcnyesinde Medical Park ve Liv Hospital hastanelerini bulunduran MLP Care\u2019de ger\u00e7ekle\u015ftirilecek pilot \u00e7al\u0131\u015fma ile sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 i\u00e7in etkin dijital bir platform kurulmas\u0131; uyar\u0131lar ve \u00f6neriler ile tan\u0131 s\u00fcrecinin desteklenmesi i\u00e7in ortam haz\u0131rlanmas\u0131 hedefleniyor.<\/p>\n\n\n\n

Hem ya\u015fam kalitesi iyile\u015ftirilecek hem de sa\u011fl\u0131k maliyetleri azalt\u0131lacak<\/strong><\/p>\n\n\n\n

Yap\u0131lan i\u015f birli\u011finin, sa\u011fl\u0131k sekt\u00f6r\u00fcn\u00fcn modern teknolojilerle kamu politikalar\u0131n\u0131 destekleyici yakla\u015f\u0131m\u0131n\u0131n en iyi \u00f6rneklerinden biri oldu\u011funu ifade eden MLP Care Dijital Tan\u0131 Direkt\u00f6r\u00fc Dr. Sinan \u015eahin, \u201cMLP Care Grubu olarak, sekt\u00f6rdeki 30 y\u0131l\u0131 a\u015fk\u0131n k\u00f6kl\u00fc deneyimimiz, imza att\u0131\u011f\u0131m\u0131z bilimsel \u00e7al\u0131\u015fmalar ile \u00fclkemizde ve d\u00fcnyada \u00f6nde gelen sa\u011fl\u0131k gruplar\u0131 aras\u0131nda yer alman\u0131n sorumlulu\u011fuyla yeniliklerin i\u00e7inde olmay\u0131 s\u00fcrd\u00fcr\u00fcyoruz. Proje,nadir hastal\u0131klar\u0131 olan binlerce hastan\u0131n y\u0131llar s\u00fcrebilen te\u015fhis s\u00fcrecini belirgin \u00f6l\u00e7\u00fcde k\u0131saltarak do\u011fru tan\u0131ya ve tedaviye eri\u015fimini h\u0131zland\u0131racak. \u00dclke sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan ise bu i\u015f birli\u011finin \u00f6nemi, hem hastalar\u0131n ya\u015fam kalitesinin do\u011frudan iyile\u015ftirilmesi hem de yanl\u0131\u015f veya gecikmi\u015f tan\u0131lardan kaynaklanan uzun vadeli sa\u011fl\u0131k sistemi maliyetlerinin \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131lmas\u0131 olacakt\u0131r. Ayr\u0131ca, t\u0131bb\u0131n her alan\u0131nda olu\u015fturulacak veri havuzlar\u0131 ile bu de\u011ferli \u00e7al\u0131\u015fmalar; gelecekteki yeni tan\u0131 ve tedavi y\u00f6ntemlerinin geli\u015ftirilmesi ve sa\u011fl\u0131k politikalar\u0131n\u0131n daha do\u011fru planlanmas\u0131 gibi topluma katk\u0131 sa\u011flayan kritik bir bilimsel zemin de olu\u015fturmu\u015f olacak\u201d dedi.<\/p>\n\n\n\n

Alexion olarak, 30 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir nadir hastal\u0131klarla m\u00fccadelede yenilik\u00e7i \u00e7\u00f6z\u00fcmler geli\u015ftirme vizyonuyla hareket ettiklerini belirten Alexion, AstraZeneca Nadir Hastal\u0131klar T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc Derya K\u00f6ker, \u201cBilimin \u00f6nc\u00fcl\u00fc\u011f\u00fcnde tasarlad\u0131\u011f\u0131m\u0131z d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc tedavilerimiz bug\u00fcn 70\u2019ten fazla \u00fclkede hastalara ula\u015f\u0131rken, s\u00fcrd\u00fcr\u00fclebilir ilerleme i\u00e7in payda\u015flar\u0131m\u0131zla g\u00fc\u00e7l\u00fc i\u015f birlikleri kurman\u0131n \u00f6nemine inan\u0131yoruz. 2010’dan bu yana T\u00fcrkiye\u2019de aktif olarak faaliyet g\u00f6steriyor; \u00fclkemizin dijital d\u00f6n\u00fc\u015f\u00fcm kapasitesi ve dinamik sa\u011fl\u0131k stratejileriyle bu alanda d\u00fcnya \u00e7ap\u0131nda \u00f6rnek lider \u00fclke olma potansiyeline inan\u0131yoruz. MLP Care ve Evideep ile ba\u015flatt\u0131\u011f\u0131m\u0131z dijital d\u00f6n\u00fc\u015f\u00fcm projesinin, nadir hastal\u0131\u011fa sahip bireylerin do\u011fru tan\u0131ya daha h\u0131zl\u0131 ve etkin ula\u015fmalar\u0131n\u0131 sa\u011flayarak sa\u011fl\u0131kta f\u0131rsat e\u015fitli\u011fine katk\u0131 sa\u011flayaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcyoruz. Yerli teknolojiyi ve veri odakl\u0131 y\u00f6netimi merkeze alarak hastalar\u0131n ya\u015fam kalitesinde d\u00f6n\u00fc\u015f\u00fcm yaratmay\u0131 hem sorumlulu\u011fumuz hem de en b\u00fcy\u00fck motivasyon kayna\u011f\u0131m\u0131z olarak g\u00f6r\u00fcyoruz. T\u00fcrkiye\u2019de nadir hastal\u0131klara sahip her bireyin h\u0131zl\u0131 tan\u0131 imkan\u0131na eri\u015fimini m\u00fcmk\u00fcn k\u0131lmak amac\u0131yla payda\u015flar\u0131m\u0131zla i\u015f birli\u011fi yapmaktan b\u00fcy\u00fck bir gurur duyuyor, bu projenin hem \u00fclkemize hem de Alexion AstraZeneca Nadir Hastal\u0131klar\u2019a de\u011fer kataca\u011f\u0131na y\u00fcrekten inan\u0131yoruz\u201d ifadelerini kulland\u0131.<\/p>\n\n\n\n

Evideep AG CEO\u2019su Bar\u0131\u015f Erdo\u011fan ise \u015funlar\u0131 s\u00f6yledi:<\/p>\n\n\n\n

\u201cTeknolojinin getirdi\u011fi imkanlar ile yapay zeka, nadir hastal\u0131klar\u0131n te\u015fhis s\u00fcresini k\u0131saltma, hasta takibini iyile\u015ftirme ve ki\u015fiselle\u015ftirilmi\u015f tedavi y\u00f6ntemleri geli\u015ftirme konular\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7an f\u0131rsatlar sunuyor. \u00d6zellikle b\u00fcy\u00fck veri analizi ve makine \u00f6\u011frenimi sayesinde, y\u0131llar s\u00fcrebilen tan\u0131 s\u00fcre\u00e7leri \u00e7ok daha h\u0131zl\u0131 ve g\u00fcvenilir h\u00e2le geliyor. Alexion AstraZeneca Nadir Hastal\u0131klar, MLP CARE ve Evideep aras\u0131ndaki bu i\u015f birli\u011fi, hem hekimlerin karar s\u00fcre\u00e7lerini destekliyor hem de hastalar\u0131n ya\u015fam kalitesini art\u0131rmay\u0131 hedefliyor. Bu kapsamda geli\u015ftirilen yenilik\u00e7i projeler, nadir hastal\u0131klar\u0131n daha erken tespit edilmesine, etkin tedavi planlar\u0131n\u0131n olu\u015fturulmas\u0131na ve toplumda fark\u0131ndal\u0131\u011f\u0131n artmas\u0131na katk\u0131 sa\u011fl\u0131yor. Bu d\u00f6n\u00fc\u015f\u00fcm, yaln\u0131zca t\u0131bbi bir ilerleme de\u011fil; ayn\u0131 zamanda sosyal bir sorumluluk alan\u0131 olarak da b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor. Teknolojinin insan hayat\u0131n\u0131 kolayla\u015ft\u0131rma g\u00fcc\u00fcn\u00fc sa\u011fl\u0131k ekosistemine dahil eden bu yakla\u015f\u0131m\u0131n, gelece\u011fin sa\u011fl\u0131k hizmetlerinin en kritik yap\u0131ta\u015flar\u0131ndan biri olarak de\u011ferlendirilece\u011fine inan\u0131yorum.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

MLP Care, Alexion AstraZeneca Nadir Hastal\u0131klar ve Evideep, nadir hastal\u0131klar konusunda yapay zeka kullan\u0131m\u0131n\u0131 hedefleyen ortak bir dijital d\u00f6n\u00fc\u015f\u00fcm projesine imza att\u0131. \u00dc\u00e7 kurumun i\u015f birli\u011fiyle hayata ge\u00e7irilecek PNH Tan\u0131s\u0131 i\u00e7in Dijital D\u00f6n\u00fc\u015f\u00fcm Projesi, T\u00fcrkiye\u2019de nadir hastal\u0131klar\u0131n erken tan\u0131s\u0131ndaki \u00f6nc\u00fc dijital giri\u015fimlerden biri olacak.<\/p>\n","protected":false},"author":1,"featured_media":4436,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4440"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4440"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4440\/revisions"}],"predecessor-version":[{"id":4442,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4440\/revisions\/4442"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4436"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}